Literature DB >> 24955324

Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables.

Simona Vuletic1, Hal Kennedy1, John J Albers1, Joep Killestein2, Hugo Vrenken3, Dieter Lütjohann4, Charlotte E Teunissen5.   

Abstract

Apolipoprotein E (apoE), phospholipid transfer protein (PLTP) activity, lipids, total tau and beta amyloid 1-42 (Aβ42) were measured in cerebrospinal fluid (CSF) from controls (n=38) and multiple sclerosis (MS) patients (n=91). ApoE and PLTP activity were significantly reduced in MS compared to non-inflammatory disease controls (NINDC; p<0.05). In NINDC and MS, apoE correlated with PLTP activity (rs=0.399 and 0.591, respectively), Aβ42 (rs= 0.609 and 0.483, respectively), and total tau (rs=0.748 and 0.380, respectively; all p<0.05). CSF apoE and PLTP significantly contributed to the variance of the normalized brain volume (NBV) and T2 lesion volume in MS (p<0.001 and p<0.05, respectively). ApoE correlated with CSF cholesterol and 24-hydroxycholesterol in all groups; PLTP activity correlated with CSF cholesterol in controls (p<0.05).

Entities:  

Keywords:  apolipoprotein E; atrophy; biomarkers; cerebrospinal fluid; multiple sclerosis; phospholipid transfer protein

Year:  2014        PMID: 24955324      PMCID: PMC4061752          DOI: 10.1016/j.msard.2014.01.004

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  38 in total

1.  CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis.

Authors:  D Chiasserini; M Di Filippo; A Candeliere; F Susta; P L Orvietani; P Calabresi; L Binaglia; P Sarchielli
Journal:  Eur J Neurol       Date:  2008-07-15       Impact factor: 6.089

2.  Effects of APOE on brain white matter microstructure in healthy adults.

Authors:  Lars T Westlye; Ivar Reinvang; Helge Rootwelt; Thomas Espeseth
Journal:  Neurology       Date:  2012-10-24       Impact factor: 9.910

3.  The association between apolipoprotein E and traumatic brain injury severity and functional outcome in a rehabilitation sample.

Authors:  Jennie Ponsford; Anna McLaren; Michael Schönberger; Richard Burke; Dion Rudzki; John Olver; Michael Ponsford
Journal:  J Neurotrauma       Date:  2011-08-08       Impact factor: 5.269

4.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

Review 5.  The synthesis and transport of lipids for axonal growth and nerve regeneration.

Authors:  J E Vance; R B Campenot; D E Vance
Journal:  Biochim Biophys Acta       Date:  2000-06-26

6.  Changes in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination.

Authors:  N Rifai; R H Christenson; B B Gelman; L M Silverman
Journal:  Clin Chem       Date:  1987-07       Impact factor: 8.327

7.  Paradoxical effects of apolipoprotein E on cognitive function and clinical progression in mice with experimental autoimmune encephalomyelitis.

Authors:  Catherine A Dayger; Jenna S Rosenberg; Clayton Winkler; Scott Foster; Ellen Witkowski; Ted S Benice; Larry S Sherman; Jacob Raber
Journal:  Pharmacol Biochem Behav       Date:  2012-11-30       Impact factor: 3.533

8.  Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis: a meta-analysis of 6977 subjects.

Authors:  Yan-Wei Yin; Yun-Dong Zhang; Jing-Zhou Wang; Bing-Hu Li; Qing-Wu Yang; Chuan-Qin Fang; Chang-Yue Gao; Jing-Cheng Li; Li-Li Zhang
Journal:  Gene       Date:  2012-09-13       Impact factor: 3.688

Review 9.  Altered lipid metabolism in brain injury and disorders.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher
Journal:  Subcell Biochem       Date:  2008

10.  Apolipoprotein E protects astrocytes from hypoxia and glutamate-induced apoptosis.

Authors:  Shuai Zhou; Haitao Wu; Chun Zeng; Xuehua Xiong; Shuang Tang; Zhaohua Tang; Xiaochuan Sun
Journal:  FEBS Lett       Date:  2012-12-10       Impact factor: 4.124

View more
  6 in total

Review 1.  The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis.

Authors:  Xian-Cheng Jiang; Yang Yu
Journal:  Curr Atheroscler Rep       Date:  2021-01-26       Impact factor: 5.113

2.  APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations.

Authors:  Mitsuru Shinohara; Takahisa Kanekiyo; Longyu Yang; Duane Linthicum; Motoko Shinohara; Yuan Fu; Laura Price; Jessica L Frisch-Daiello; Xianlin Han; John D Fryer; Guojun Bu
Journal:  Ann Neurol       Date:  2016-03-29       Impact factor: 10.422

3.  Dietary cholesterol promotes repair of demyelinated lesions in the adult brain.

Authors:  Stefan A Berghoff; Nina Gerndt; Jan Winchenbach; Sina K Stumpf; Leon Hosang; Francesca Odoardi; Torben Ruhwedel; Carolin Böhler; Benoit Barrette; Ruth Stassart; David Liebetanz; Payam Dibaj; Wiebke Möbius; Julia M Edgar; Gesine Saher
Journal:  Nat Commun       Date:  2017-01-24       Impact factor: 14.919

4.  Elevated Phospholipid Transfer Protein in Subjects with Multiple Sclerosis.

Authors:  Roy A Garvin
Journal:  J Lipids       Date:  2015-08-12

5.  Relapsing-Remitting Multiple Sclerosis diagnosis from cerebrospinal fluids via Fourier transform infrared spectroscopy coupled with multivariate analysis.

Authors:  Dilek Yonar; Levent Ocek; Bedile Irem Tiftikcioglu; Yasar Zorlu; Feride Severcan
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

6.  Expression profiles of cholesterol metabolism-related genes are altered during development of experimental autoimmune encephalomyelitis in the rat spinal cord.

Authors:  Irena Lavrnja; Kosara Smiljanic; Danijela Savic; Aleksandra Mladenovic-Djordjevic; Katarina Tesovic; Selma Kanazir; Sanja Pekovic
Journal:  Sci Rep       Date:  2017-06-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.